MILD AND SITE-SELECTIVE 18F-LABELING OF SMALL MOLECULES AND/OR BIOMOLECULES VIA A THIOL-REACTIVE SYNTHON

    公开(公告)号:WO2020009945A1

    公开(公告)日:2020-01-09

    申请号:PCT/US2019/039929

    申请日:2019-06-28

    Abstract: Site-selective conjugation to biomolecules via thiol-based chemistry is superior to the unselective modification of lysine residues, which produce a mixed product and can potentially interfere with binding affinity of the biomolecule. However, in physiological environments, the maleimide-thiol conjugation product which is the current gold-standard for site-selective thiol-conjugation can be susceptible to hydrolysis or a retro-Michael reaction via exchange with reactive thiols such as those in albumin or glutathione residues yet the degradation is relatively slow. Therefore, for in vivo studies, the maleimide-thiol conjugation proposes instability issues. The compositions and methods disclosed herein provide an alternative thiol-based linkage, one that overcomes the instability issues with conventional reagents and methods. The compositions and methods disclosed herein are useful in various contexts, for example, for 18 F-labeling of peptides/proteins in the preparation of positron emission tomography (PET) probes.

    INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE
    4.
    发明申请
    INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE 审中-公开
    α-氨基-β-羧基琥珀酸半醛脱羧酶抑制剂

    公开(公告)号:WO2018069532A1

    公开(公告)日:2018-04-19

    申请号:PCT/EP2017/076252

    申请日:2017-10-13

    Abstract: The present disclosure discloses compounds capable of modulating the activity of α- amino-β-carboxymuconic acid semialdehyde decarboxylase (ACMSD), which are useful for the prevention and/or the treatment of diseases and disorders associated with defects in NAD + biosynthesis, e.g., metabolic disorders, neurodegenerative diseases, chronic inflammatory diseases, kidney diseases, and diseases associated with ageing. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament.

    Abstract translation: 本公开公开了能够调节α-氨基-β-羧基粘康酸半醛脱羧酶(ACMSD)活性的化合物,其可用于预防和/或治疗与以下疾病和病症有关的疾病和病症 NAD +生物合成中的缺陷,例如代谢紊乱,神经退行性疾病,慢性炎症疾病,肾脏疾病和与衰老相关的疾病。 本申请还公开了包含所述化合物的药物组合物以及这些化合物作为药物的用途。

    FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF
    5.
    发明申请
    FLUORINATED TETRAHYDRONAPHTHYRIDINYL NONANOIC ACID DERIVATIVES AND USES THEREOF 审中-公开
    氟化四氢萘基蒽醌无水酸衍生物及其用途

    公开(公告)号:WO2016134223A3

    公开(公告)日:2016-10-20

    申请号:PCT/US2016018612

    申请日:2016-02-19

    CPC classification number: C07D471/04

    Abstract: The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating fibrosis, macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

    Abstract translation: 本发明涉及式I的氟化化合物和合成这些化合物的方法。 本发明还涉及含有本发明氟化化合物的药物组合物以及治疗纤维化,黄斑变性,糖尿病性视网膜病(DR),黄斑水肿,糖尿病性黄斑水肿(DME)和视网膜静脉阻塞后的黄斑水肿(RVO ),通过将这些化合物和药物组合物给予有需要的受试者。

Patent Agency Ranking